Background
Eliciting patient preferences for their postoperative experience has become more important when trying to improve the quality of the case, and in addressing cost containment in healthcare. 1 Pain is a sensory experience that is unpleasant and multidimensional. It may vary in quality (sharp versus dull), intensity (mild, moderate or severe), duration (transient, intermittent or prolonged), and referral (deep, superficial, local or diffuse). 2 Uncontrolled pain can lead to prolonged patient stays in the post anesthesia care unit (PACU), delayed discharge, and can increase the incidence of unintended hospital admission after a day surgery procedure. If inadequately treated, postoperative pain can lead to physiologic changes caused by inflammatory, metabolic, and endocrine responses, especially in acute pain. 3 There are many reasons for surgical morbidity. Extended stays, unplanned readmissions, and patient morbidity have been shown to have significant economic consequences for health systems when patients receive inadequate postoperative pain management. 4 Thirty-one percent of total pharmacy costs are related to postoperative analgesia management, with pharmacy costs being 1% of the total cost of surgery. 4 Timely and safe patient discharge is directly related to adequate postoperative pain control.
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There are many challenges for the practitioner when it comes to management of postoperative pain.
An essential part of providing patient comfort and safety is the use of sedative-hypnotics and analgesics in an effective manner. 6 Adequate pain control is important in preventing the negative outcomes associated with surgery such as nausea, vomiting, high heart rate and blood pressure, a decrease in adequate ventilation, and other issues during the postoperative period. 7, 8 Postoperative nausea and Surgeons and anesthesia providers may use a non-opioid technique to manage pain during the perioperative period to minimize analgesic medication side effects. 5 The approach to improving postoperative outcome and reduce convalescence can be impacted b multimodal perioperative pain management. 3 Optimal dynamic (movement) pain is thought to be a prerequisite for early postoperative recovery. 9 With an increased understanding of the pathophysiology of acute pain, no one intervention seems to be effective with moderate pain or greater. 7, 10 The development of new drugs and anesthetic techniques for analgesic delivery has also had an effect on improvement in optimal treatment of postoperative pain. 10 Traditional unimodal (opioid only) treatment therapies may improve pain at rest, but have not been effective in providing optimal pain relief due to dynamic pain (pain due to movement), and thus, a faster recovery is not facilitated. 3, 10 Multimodal analgesia is a method to control postoperative pain by administering a combination of opioid and non-opioid analgesics to patients that act on different areas. 11 This method of controlling postoperative pain not only decreases the amount of opioids needed to control pain, but also reduces the risks associated with opioids, i.e. respiratory depression, nausea, vomiting, itching, etc.
7,11
Surgical trauma causes a major cytokine and neuroendocrine stress response. 12 The stress response has predictable metabolic consequences characterized by increases in steroid hormone production and an increase in catecholamines. When a person is injured, immune mediators, such as cytokines, are released to direct the inflammatory response. Cytokines are essential to healing, but can lead to hemodynamic instability, and metabolic derangements when an exaggerated production occurs.
Alpha-2 agonists target an important receptor causing reduction in noradrenaline release, thereby inducing inhibition of the sympathetic response. Inhibition of noradrenaline release causes attenuation of excitation in the central nervous system, particularly the locus coeruleus, where the analgesic and sedative effects originate. 13 Often the choice of analgesic combinations depends on the profile of side effects they have, as well as the analgesic effect. 3 Morphine and its chemical equivalents are commonly-used opioid analgesics, but as their doses increase, so do the side effects. 7 The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has suggested that postoperative opioid analgesics used in excess leads to decreased patient satisfaction. 5 The development of dexmedetomidine was an attempt to improve on the time-tested sedative-hypnotic and analgesics already on the market. 6 Dexmedetomidine is a highly selective alpha-2 agonist that has analgesic and sedative-sparing properties. 14 Use of dexmedetomidine has been shown to cause a 30-50% reduction in opioid requirements on a consistent basis. 15 However, dexmedetomidine does not approximate the potency of opioids. When opioid relief is not optimal (i.e. neuropathic pain), alpha-2 agonists can offer specific advantages.
Dexmedetomidine is more effective than clonidine (another alpha-2 agonist) because it binds to the receptors eight times tighter, and it is shorter acting. 6 Its use causes sedation from binding to receptors in the locus coeruleus, and analgesia by binding to receptors in the spinal cord. effects. 17 Studies show confounding factors regarding alpha-2 agonists in the perioperative period, in regards to whether sedative or analgesic effects are responsible for the reduced opioid requirements of the patient receiving them. 16 Despite high levels of sedation, dexmedetomidine has not been associated with respiratory suppression. 14 Additionally, dexmedetomidine has been shown to have hypnotic and anxiolytic properties. 18 Continuous infusions of dexmedetomidine at rates between 0.4mcg/kg/hr and 0.7mcg/kg/hr have been shown to decrease postoperative morphine requirements and improve pain control. 19 These aspects make it an attractive option in anesthesia delivery.
Consistent with its pharmacologic sympatholytic effects, dexmedetomidine decreases the heart rate and arterial blood pressure. 15 Therefore, careful patient selection is needed when considering the use of dexmedetomidine in the perioperative period. 6 Traditional unimodal postoperative pain management has not been effective in accelerating recovery from surgery-induced organ dysfunction. 10 Dexmedetomidine might be useful in the postoperative period due to its analgesic sparing properties, sedative properties, and lack of respiratory depression. 14, 18, 20 Avoiding postoperative pain was shown to be a major concern for day surgery patients. 
Inclusion criteria

Types of participants
The review will consider studies that include patients over the age of 18 years of age, receiving general inhalation anesthesia. Patients must have had an infusion of dexmedetomidine intra-operatively during their procedure, with or without additional opioids. Patients must have been extubated (endotracheal tube removed) at the conclusion of the surgical procedure, in the operating room, to allow for immediate postoperative pain assessment. Therefore, patients transported directly to the PACU, or the intensive care unit (ICU), with endotracheal tubes in place will be excluded from this review.
Variations will be allowed in the following categories due to a wide range of patient types, patient weights, co-morbidities, surgeon preferences/skills, anesthesia provider preferences/skills, unforeseen and uncontrollable intra-operative issues, i.e. vital signs, variables, bleeding, etc.
Types of intervention(s)
The review will consider studies that examined the impact of intraoperative dexmedetomidine infusion, during a general inhalation anesthetic, with or without concomitant opioids, on immediate postoperative pain. Intra-operative dexmedetomidine infusions of all rates will be included. The comparator will be no intra-operative dexmedetomidine medication via any route during a general inhalation anesthetic.
Types of outcomes
The review will consider studies that include the following outcome measures: postoperative pain and medication requirements during the first four hours after surgery. Postoperative pain will be measured by patients who reported Visual Analog Scores (VAS) during the first four postoperative hours.
Types of studies
The review will consider both experimental and epidemiological study designs including randomized controlled trials (RCTs), non-randomized controlled trials, quasi-experimental, before and after studies, prospective and retrospective cohort studies, case control studies and analytical cross sectional studies for inclusion. The quantitative component of the review will also consider descriptive epidemiological studies including case series, individual case reports, and descriptive cross sectional studies for inclusion to identify and evaluate current best practice evidence regarding the use of dexmedetomidine infusions and post-operative pain management.
Search strategy
The search strategy aims to find both published and unpublished studies. A three-step search strategy will be utilized in this review. An initial limited search of MEDLINE and CINAHL will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe an article. A second search using all identified keywords and index terms will then be undertaken across all included databases. Thirdly, the reference list of all identified reports and articles will be searched for additional studies.
The search strategy will attempt to identify all unpublished and published studies in the English language, between 1999 and December 2012, as 1999 was when dexmedetomidine was approved for use as a continuous infusion in the United States. 
Assessment of methodological quality
Papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardized critical appraisal instruments from the Joanna Briggs
Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix I).
Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Data collection
Data will be extracted from papers included in the review by the primary reviewer and a second independent reviewer, using the standardized data extraction tool from JBI-MAStARI (Appendix II). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives. The author of the primary study will be contacted for any missing information or to clarify unclear data.
Data synthesis
Quantitative papers will be pooled in statistical meta-analysis, where possible, using JBI-MAStARI.
Double data entry will be used for all results. Odds ratio (for categorical data) and weighed mean differences (for continuous data) and the 95% confidence intervals will be calculated for analysis.
Heterogeneity will be assessed using the standard Chi-square and also explored using subgroup analyses based on the different study designs included in this review. variations in treatment effect will be explored using subgroup analyses, such as population differences, intervention differences, study quality, and outright exclusions. The findings will be presented in narrative form if statistical pooling is not possible.
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